RSLS - ReShape Lifesciences Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.42
-0.02 (-1.39%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close1.44
Open1.44
Bid1.32 x 600
Ask1.50 x 2300
Day's Range1.40 - 1.44
52 Week Range1.23 - 6.45
Volume59,536
Avg. Volume278,037
Market Cap42.539M
Beta2.47
PE Ratio (TTM)N/A
EPS (TTM)-4.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • ReShape Lifesciences Reports Preliminary Fourth Quarter and Full Year 2017 Revenue
    PR Newswire20 days ago

    ReShape Lifesciences Reports Preliminary Fourth Quarter and Full Year 2017 Revenue

    SAN CLEMENTE, Calif., Feb. 1, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today preliminary revenue results for the fourth quarter and year ended December 31, 2017. Preliminary and unaudited revenue for fourth quarter 2017, which includes revenue resulting from the October 2, 2017 acquisition of ReShape Medical, is expected to be approximately $795,000, with approximately $720,000 in revenue from ReShape® Balloons and approximately $75,000 in vBloc® revenue generated during the fourth quarter of 2017. Preliminary and unaudited revenue for full year 2017, which includes fourth quarter revenue resulting from the October 2, 2017 acquisition of ReShape Medical, is expected to be approximately $1.3 million, with approximately $720,000 in revenue from ReShape Balloons and approximately $570,000 in vBloc revenue that was generated during the year ended December 31, 2017.

  • ReShape Lifesciences Announces 2017 Weight Loss Contest Winner
    PR Newswire27 days ago

    ReShape Lifesciences Announces 2017 Weight Loss Contest Winner

    The contest winner lost a total of 80 pounds, or 41% total weight loss (TWL), with 60 pounds, or 28% TWL, lost during the 6-month ReShape Balloon implant period, followed by continued weight loss of the remaining 20 pounds after device removal. The patient, a female, age 53, had the ReShape Balloon placed by Dr. Vivek Kumbhari, MD, Director of Endoscopy at Johns Hopkins Bayview Medical Center & Director of Bariatric Endoscopy at Johns Hopkins Weight Management Center.

  • ReShape Lifesciences, Inc. :RSLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
    Capital Cube2 months ago

    ReShape Lifesciences, Inc. :RSLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017

    Categories: Yahoo FinanceGet free summary analysis ReShape Lifesciences, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ReShape Lifesciences, Inc. – LivaNova Plc, Misonix, Inc. and Medtronic plc (LIVN-US, MSON-US and MDT-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai
    PR Newswire2 months ago

    ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai

    SAN CLEMENTE, Calif., Dec. 13, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases announced today that it has received a significant order for its ReShape® Integrated Dual Balloon System from Al Zahrawi Medical, a healthcare focused company specializing in medical, surgical, diagnostic and analytical lab and nuclear medicine supplies with presence throughout the United Arab Emirates (UAE) and Qatar.  This order, the second since Al Zawhari's initial stocking order in August 2017, is to support increased demand for the Reshape Integrated Dual Balloon System from a leading hospital customer's growing bariatric program in Dubai.

  • PR Newswire3 months ago

    ReShape Lifesciences Announces Coverage of ReShape Dual Balloon by Major Telecom Company

    SAN CLEMENTE, Calif., Dec. 4, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that their ReShape Integrated Dual Balloon technology has been granted employee coverage through a supplemental coverage policy at a multinational telecommunications corporation that provides mobile telephone, fixed telephone and broadband subscription television services. "Obesity is an epidemic with a global economic impact of over $2 trillion, and obese adults spend over 40% more on healthcare than those at a healthy weight," said Dan Gladney, President, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. The telecommunications company employs over 260,000 people worldwide, and the ReShape Dual Balloon is the only intragastric balloon listed and exclusively covered for certain of these employees as a benefit through one of their internal benefits programs that partners with many corporations for coverage of their employees and retirees.

  • ReShape Lifesciences Announces Third Quarter 2017 Financial Results
    PR Newswire3 months ago

    ReShape Lifesciences Announces Third Quarter 2017 Financial Results

    SAN CLEMENTE, Calif. , Nov. 14, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • ReShape Lifesciences Presents New Data on Obesity Technologies
    PR Newswire4 months ago

    ReShape Lifesciences Presents New Data on Obesity Technologies

    SAN CLEMENTE, Calif., Nov. 3, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented this week at the ObesityWeek 2017 conference in Washington D.C. "Obesity has become a global epidemic that involves significant health issues, comorbidities, and high associated costs to the healthcare system," said Dan Gladney, President, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. The presentation discussed 342 patients that were implanted with the ReShape® Integrated Dual Balloon at a multicenter bariatric practice (mean age of 45, average weight of 231 lbs., average Body Mass Index (BMI) of 38, 76% female).

  • ReShape Lifesciences To Host Third Quarter Conference Call On November 14, 2017
    PR Newswire4 months ago

    ReShape Lifesciences To Host Third Quarter Conference Call On November 14, 2017

    SAN CLEMENTE, Calif. , Oct. 31, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced ...